Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Sanofi (SNY)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
54.40+1.34 (+2.53%)
At close: 04:00PM EDT
54.40 0.00 (0.00%)
After hours: 07:58PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close53.06
Open54.04
Bid53.30 x 1200
Ask54.38 x 800
Day's Range53.78 - 54.56
52 Week Range46.93 - 58.10
Volume1,859,606
Avg. Volume2,225,903
Market Cap135.854B
Beta (5Y Monthly)0.36
PE Ratio (TTM)19.40
EPS (TTM)2.80
Earnings DateN/A
Forward Dividend & Yield1.80 (3.30%)
Ex-Dividend DateMay 26, 2022
1y Target Est70.75
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
-16% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for SNY

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Sanofi
    Technical Assessment: Bearish in the Intermediate-TermTuesday was another wild day in the stock market, as investors gear up for today's CPI and Thursday's PPI. Never a dull moment in 2022! The S&P 500 was up over 75 points in the first five minutes (almost 2%) while the Nasdaq and the QQQs were up almost 3%. By 11:00, all three indices were lower, with the "500" off 35 points. By 2:00, the "500" was back up by almost 50 points, and then gave that up, finishing with a small gain.
    Rating
    Fair Value
    Economic Moat
    11 days agoArgus Research
View more
Advertisement
Advertisement